Aurobindo bags one more cephalosporin from USFDA
- Category: More News
- Published on Tuesday, 30 January 2007 02:00
- Hits: 3237
HYDERABAD, India | Jan 29, 2007 | Aurobindo Pharma is pleased to announce that the company has received one more approval from USFDA for Cefadroxil capsules 500mg. Cefadroxil is a first generation Cephalosporin antibiotic. It is used in a wide variety of bacterial infections (respiratory, skin & soft tissue, and Urinary tract infections).
Cefadroxil is Aurobindo’s 37th USFDA approval in total and third approval from its cephalosporin range. Cefadroxil 500mg capsules commands a market of over 21 mio dollars in the USA.
About Aurobindo Pharma Limited:
Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for most of the targeted API and formulation facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics.
The formulation portfolio is built on six technology platforms such as immediate release generics, SR/CR generics, Orally disintegrating/Mouth dissolving generics, Combination products, Sterile/Lyophilized generics and Liquids/Dry syrups. Aurobindo has filed over 100 DMFs and 75 ANDAs for the USA market alone in addition to filings in other countries. The pace of filings is matched by rapid product approvals from various markets. Till date Aurobindo received 37 ANDA approvals (both final and tentative) from US alone. Aurobindo operates in over 100 countries and markets over 180 APIs and 250 formulations
For further information, please contact:
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
SOURCE: Aurobindo Pharma Limited